Now we have multiple vaccines released and are a month into distribution, what does phase one, two, and three (and beyond) look like. Join us as Phyllis Arthur, Vice President for Infectious Diseases and Diagnostics Policy at the Biotechnology Innovation Organization (BIO) talks to us about vaccine testing and safety for the general population, distribution, vaccine facts and fiction, and what each of us can do to ensure we move past this pandemic and future ones.

January 26, 2021 | 12:00 p.m. | Zoom

About the speaker:

Phyllis Arthur is Vice President for Infectious Diseases and Diagnostics Policy at the Biotechnology Innovation Organization (BIO). In this role, Ms. Arthur is responsible for working with member companies in vaccines, antimicrobial resistance, molecular diagnostics, and biodefense on policy, legislative, and regulatory issues.

Ms. Arthur joined BIO in July 2009 as the Director of Healthcare Regulatory Affairs. Prior to joining BIO, she worked in numerous marketing and sales positions for Merck & Co Inc in their Vaccine Division. Over her 16-year career in vaccines, Ms. Arthur launched several exciting new vaccines in the United States and internationally, including the first HPV vaccine, GARDASIL. During her years in Marketing, she worked closely with clinical and academic thought leaders in infectious diseases, oncology, and public health. In addition, Ms. Arthur also led a large vaccine sales organization of over 75 representatives and managers covering 14 states.

Before graduate school, Ms. Arthur worked as a research assistant for two economists at the Brookings Institution in Washington, DC. There she conducted economic analyses related to savings and investment policies for the OECD countries.

Ms. Arthur received her B.A. in 1987 in Economics and International Politics from Goucher College and her M.B.A. in 1991 from the Wharton School of Business at the University of Pennsylvania.